Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Clozapine N-oxide (CNO) (freebase) (HB1807)
Description:Prototypical DREADD activator. Clozapine metabolite.
Purity:>98%
- Description:
Dihydrochloride salt of CNO - the prototypical DREADD activator
Purity:>98%
Compound 112254 hydrochloride (HB3847)
Description:Adiponectin receptor (AdipoR) agonist
Purity:>98%
CP 94253 dihydrochloride (HB1671)
Description:Potent, selective 5-HT1B receptor agonist
Purity:>98%
Cyclothiazide (HB0221)
Description:AMPA receptor positive allosteric modulator. Inhibits AMPAR desensitization.
Purity:>98%